Candriam SCA’s Biogen BIIB Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $83M | Buy |
384,326
+2,558
| +0.7% | +$489K | 0.37% | 53 |
|
|
2026
Q1 | $70M | Buy |
381,768
+51,296
| +16% | +$9.45M | 0.36% | 55 |
|
|
2025
Q4 | $58.2M | Buy |
330,472
+171,651
| +108% | +$28M | 0.29% | 76 |
|
|
2025
Q3 | $22.2M | Sell |
158,821
-4,494
| -3% | -$607K | 0.12% | 167 |
|
|
2025
Q2 | $20.5M | Sell |
163,315
-23,465
| -13% | -$2.92M | 0.12% | 161 |
|
|
2025
Q1 | $25.6M | Sell |
186,780
-15,184
| -8% | -$2.17M | 0.16% | 132 |
|
|
2024
Q4 | $30.9M | Sell |
201,964
-10,493
| -5% | -$1.77M | 0.18% | 112 |
|
|
2024
Q3 | $41.2M | Sell |
212,457
-54,002
| -20% | -$11.3M | 0.24% | 92 |
|
|
2024
Q2 | $61.8M | Sell |
266,459
-583
| -0.2% | -$127K | 0.37% | 58 |
|
|
2024
Q1 | $57.6M | Buy |
267,042
+81,757
| +44% | +$19.1M | 0.37% | 62 |
|
|
2023
Q4 | $47.9M | Sell |
185,285
-48,674
| -21% | -$12M | 0.33% | 74 |
|
|
2023
Q3 | $60.1M | Buy |
233,959
+62
| +0% | +$16.6K | 0.43% | 50 |
|
|
2023
Q2 | $66.6M | Sell |
233,897
-64,848
| -22% | -$19.3M | 0.48% | 48 |
|
|
2023
Q1 | $76.5M | Buy |
298,745
+932
| +0.3% | +$258K | 0.53% | 37 |
|
|
2022
Q4 | $82.5M | Buy |
297,813
+46,654
| +19% | +$13.2M | 0.56% | 33 |
|
|
2022
Q3 | $67.1M | Sell |
251,159
-1,034
| -0.4% | -$220K | 0.47% | 45 |
|
|
2022
Q2 | $51.4M | Buy |
252,193
+9,133
| +4% | +$1.87M | 0.42% | 57 |
|
|
2022
Q1 | $51.2M | Buy |
243,060
+25,183
| +12% | +$5.48M | 0.35% | 67 |
|
|
2021
Q4 | $52.3M | Sell |
217,877
-54,766
| -20% | -$14.1M | 0.33% | 72 |
|
|
2021
Q3 | $77.2M | Sell |
272,643
-2,397
| -0.9% | -$786K | 0.52% | 44 |
|
|
2021
Q2 | $95.2M | Sell |
275,040
-115,830
| -30% | -$35.1M | 0.65% | 29 |
|
|
2021
Q1 | $91.9M | Hold |
390,870
| – | – | 0.77% | 21 |
|
|
2020
Q4 | $95.7M | Buy |
390,870
+23,281
| +6% | +$6.01M | 0.76% | 21 |
|
|
2020
Q3 | $104M | Buy |
367,589
+26,670
| +8% | +$7.44M | 0.98% | 16 |
|
|
2020
Q2 | $91.2M | Sell |
340,919
-53,346
| -14% | -$16M | 0.96% | 15 |
|
|
2020
Q1 | $114M | Hold |
394,265
| – | – | 1.27% | 13 |
|
|
2019
Q4 | $117M | Sell |
394,265
-44,324
| -10% | -$12.3M | 1.25% | 13 |
|
|
2019
Q3 | $102M | Sell |
438,589
-186,131
| -30% | -$43.3M | 1.35% | 13 |
|
|
2019
Q2 | $145M | Sell |
624,720
-29,775
| -5% | -$6.88M | 1.81% | 6 |
|
|
2019
Q1 | $155M | Buy |
654,495
+84,754
| +15% | +$26.7M | 1.98% | 3 |
|
|
2018
Q4 | $171M | Buy |
569,741
+61,805
| +12% | +$19.7M | 2.63% | 2 |
|
|
2018
Q3 | $179M | Buy |
507,936
+205,294
| +68% | +$70.7M | 2.39% | 2 |
|
|
2018
Q2 | $87.8M | Buy |
302,642
+97,482
| +48% | +$27.4M | 1.39% | 9 |
|
|
2018
Q1 | $56.2M | Buy |
205,160
+161,000
| +365% | +$50M | 0.96% | 12 |
|
|
2017
Q4 | $14.1M | Sell |
44,160
-238,317
| -84% | -$76.5M | 0.24% | 111 |
|
|
2017
Q3 | $88.4M | Buy |
282,477
+62,876
| +29% | +$18.6M | 1.55% | 5 |
|
|
2017
Q2 | $59.6M | Buy |
219,601
+44,643
| +26% | +$11.8M | 1.12% | 13 |
|
|
2017
Q1 | $47.8M | Sell |
174,958
-7,596
| -4% | -$2.15M | 0.93% | 15 |
|
|
2016
Q4 | $51.8M | Sell |
182,554
-3,163
| -2% | -$938K | 1.19% | 10 |
|
|
2016
Q3 | $58.1M | Buy |
185,717
+19,856
| +12% | +$5.88M | 1.4% | 10 |
|
|
2016
Q2 | $40.1M | Sell |
165,861
-15,539
| -9% | -$4.1M | 1.04% | 16 |
|
|
2016
Q1 | $47M | Sell |
181,400
-61,619
| -25% | -$16.3M | 1.17% | 13 |
|
|
2015
Q4 | $74.4M | Buy |
243,019
+30,283
| +14% | +$8.7M | 1.99% | 6 |
|
|
2015
Q3 | $62.1M | Buy |
212,736
+9,530
| +5% | +$3.15M | 1.52% | 7 |
|
|
2015
Q2 | $82.1M | Buy |
203,206
+13,923
| +7% | +$5.59M | 1.71% | 6 |
|
|
2015
Q1 | $79.9M | Buy |
189,283
+1,255
| +0.7% | +$495K | 1.61% | 6 |
|
|
2014
Q4 | $63.8M | Buy |
+188,028
| New | +$60.8M | 1.33% | 7 |
|
Other funds holding BIIB
Candriam SCA's BIIB Position: Q2 2026 in Review
Candriam SCA increased its Biogen (BIIB) stake by 0.67% in Q2 2026, buying an estimated $489K and bringing the position to 384,326 shares worth $83M. The position accounts for 0.37% of the portfolio, ranked #53.
Candriam SCA first reported a position in BIIB in Q4 2014 and has held it in 47 quarters since. The position peaked at $179M in Q3 2018. 1,036 funds tracked by Wall St. Rank hold BIIB as of Q2 2026.
- Candriam SCA held 384,326 shares of Biogen worth $83M as of Q2 2026.
- Candriam SCA bought 2,558 Biogen shares in Q2 2026, an estimated $489K.
- Biogen made up 0.37% of Candriam SCA's portfolio in Q2 2026, its #53 holding.
- Candriam SCA first reported a position in Biogen in Q4 2014 and has held it in 47 quarters since.
- Candriam SCA's Biogen position peaked at $179M in Q3 2018.
- 1,036 funds tracked by Wall St. Rank held Biogen as of Q2 2026.
Based on Candriam SCA's 13F filing for Q2 2026, filed 13 Aug 2026.